Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00987948 · ClinicalTrials.gov registry record · Phase 2
Maraviroc Intensification and Peripheral Blood Monocyte HIV DNA Levels
A Phase 2 study, sponsored by University of Hawaii.
- Completed
- Registry status
- Phase 2
- Development phase
- 15
- Enrollment target
NCT00987948 is a Phase 2 study that has completed, run by University of Hawaii. The registered enrollment target is 15 participants.
The verdict
NCT00987948, a Phase 2 study, has completed, sponsored by University of Hawaii.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 15 participants
- Enrollment target
Study Summary
High levels of HIV infection within blood monocyte/macrophages (a type of white cells in the bloodstream) increases risk of dementia in HIV-infected individuals. Maraviroc (Selzentry) is a HIV medication that works by blocking the entry of HIV in cells including monocytes/macrophages that use a receptor called CCR5. The study hypothesis is that the addition of Maraviroc to a HIV antiretroviral regimen in HIV-infected individuals with high levels of HIV-infected monocyte/macrophages will lead to a decrease in the levels of infected monocyte/macrophages and to decrease in brain inflammation as studied by magnetic resonance spectroscopy (MRS, a form of MRI study).
Interventions
- DRUG maraviroc (Selzentry)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 15 participants |
| Start Date | 2010-01 |
| Est. Completion | 2013-08 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00987948
The ClinicalTrials.gov registry entry for NCT00987948 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 15 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of Hawaii, which has 77 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which maraviroc (Selzentry) is the first listed.
NCT00987948 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00987948 about?
NCT00987948 is a clinical study titled "Maraviroc Intensification and Peripheral Blood Monocyte HIV DNA Levels". High levels of HIV infection within blood monocyte/macrophages (a type of white cells in the bloodstream) increases risk of dementia in HIV-infected individuals. Maraviroc (Selzentry) is a HIV medication that works by blocking the entry of HIV in cells including monocytes/macrophages that use a rece...
What is the current status of trial NCT00987948?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 15 participants. The study started on 2010-01. Estimated completion is 2013-08.
What interventions are being tested in trial NCT00987948?
The interventions under investigation include: maraviroc (Selzentry) (DRUG).
Who is sponsoring clinical trial NCT00987948?
This trial is sponsored by University of Hawaii, which has 77 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.